belumosudil

FDA Drug Profile — Rezurock

belumosudil is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Rezurock. Available dosage form: tablet.

Drug details

Generic Name
belumosudil
Brand Names
Rezurock
Application Number
NDA214783
Sponsor
Sanofi S.R.L.
NDC Codes
2
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
BELUMOSUDIL

Indications and Usage

1 INDICATIONS AND USAGE REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.